drugset / Trial / NCT04573309
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Timeline
- Start
- 2020-09-07
- Primary completion
- 2022-06-07
- Completion
- 2022-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIOMOLIBDATE CHOLINE | Small molecule | 30 mg | Oral |